JERUSALEM - Entera Bio Ltd . (NASDAQ: NASDAQ:ENTX), a biotechnology firm specializing in the oral delivery of peptides, has successfully regained compliance with NASDAQ's minimum bid price requirement for continued listing on The NASDAQ Capital Market, the company announced today. The compliance was achieved after the company's ordinary shares maintained a closing bid price of at least $1.00 over a minimum of 10 consecutive business days, concluding on March 1, 2024.
Entera Bio is engaged in developing oral peptide therapies aimed at addressing significant unmet medical needs where tablet forms could revolutionize standard care. The company's proprietary technology platform supports a pipeline of five distinct oral peptide programs, with clinical phases ranging from Phase 1 to Phase 3 expected to commence by 2025.
Among its leading product candidates is EB613, an oral tablet treatment for post-menopausal women with osteoporosis and low bone mineral density (BMD) without prior fractures. This candidate has completed a Phase 2 study, meeting both primary and secondary endpoints, and is preparing for a Phase 3 registrational study anticipated to start in 2024.
Entera Bio is also advancing EB612 as the first oral peptide replacement therapy for hypoparathyroidism and is developing an oral oxyntomodulin tablet for obesity treatment and an oral GLP-2 peptide tablet for rare malabsorption conditions like short bowel syndrome, in collaboration with OPKO Health.
The company's progress in regaining NASDAQ compliance and advancing its clinical programs is based on the press release statement issued by Entera Bio Ltd.
InvestingPro Insights
As Entera Bio Ltd. (NASDAQ: ENTX) celebrates its compliance with NASDAQ's minimum bid price requirement, investors are keeping a close eye on the company's financial health and market performance. According to InvestingPro data, Entera Bio's market capitalization currently stands at 53.21 million USD, reflecting the market's valuation of the company. Despite the company's innovative approach to oral peptide therapies, its revenue for the last twelve months as of Q3 2023 is reported at a mere 0.01 million USD, with a significant revenue decline of 95.09%. This underscores the challenges Entera Bio faces in commercializing its product pipeline.
InvestingPro Tips reveal that Entera Bio holds more cash than debt on its balance sheet, which could provide some financial flexibility as it advances its clinical programs. Additionally, the stock has experienced a substantial return over the last week, with a 37.14% price total return, suggesting a growing investor interest in the company's potential. However, the company's P/E ratio stands at -4.55, indicating that it is not currently profitable.
For investors seeking a deeper dive into Entera Bio's performance metrics and future outlook, there are additional InvestingPro Tips available at https://www.investing.com/pro/ENTX. These tips provide insights such as the stock's volatility and the analysts' sales decline anticipation for the current year. With a total of 15 InvestingPro Tips listed, investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, offering valuable guidance for informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.